logo
Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research

Firefly Inks Latest Commercial Agreement for Use of its FDA-Cleared BNA™ Platform in Groundbreaking Precision Neuroscience Research

Yahoo14-07-2025
– Institute of Human Genetics at Heidelberg University Hospital ongoing EEG biomarker study on 15q13.3 CNVs –
– Collaboration aims to uncover novel insights into the brain's functional architecture in rare genetic conditions –
– Building and growing a license business is an increasingly important pillar of Firefly's commercial strategy –
KENMORE, N.Y., July 14, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. ('Firefly' or the 'Company') (NASDAQ: AIFF), an Artificial Intelligence ('AI') company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to highlight its ongoing collaboration with Prof. Dr. med. Christian Schaaf, Director of the Institute of Human Genetics at Heidelberg University Hospital and Chairman of Human Genetics at the Medical Faculty of Heidelberg University, on a groundbreaking study investigating the neurophysiological impact of 15q13.3 copy number variants ('CNVs'). This engagement builds on prior work between Firefly and Prof. Schaaf, including a joint publication on CHRNA7-related phenotypes.1
The current study leverages Firefly's FDA-cleared technology to analyze Electroencephalograms ('EEG') data from 30 subjects — 15 with deletions and 15 with duplications of the 15q13.3 chromosomal region. Study subjects undergo resting state and two cognitive paradigms running automatically through Firefly's BNA platform.
The study is scheduled to run through 2026, with Firefly commercially engaged to provide EEG systems, training, and full analytic support, including the comparison to its proprietary, FDA-cleared normative Resting and Event-Related Potential Cognitive tasks database.
The study aims to:
Identify electrophysiological biomarkers associated with 15q13.3 CNVs;
Characterize neurocognitive profiles linked to deletions vs. duplications; and
Support future diagnostic and therapeutic strategies for neurodevelopmental disorders.
'This collaboration reflects our shared commitment to advancing precision neuroscience,' said Gil Issachar, Chief Technology Officer of Firefly. 'By combining Heidelberg's clinical expertise with our proprietary technology, we aim to uncover novel insights into the brain's functional architecture in rare genetic conditions. But our mission goes well beyond any single study — deepening our understanding of cognitive disorders, both common and rare, is essential to transforming how we diagnose, monitor, and treat these conditions. Every insight we gain from rare genetic variants like 15q13.3 helps illuminate the broader landscape of neurodevelopmental and neuropsychiatric disorders. We believe that by decoding the brain's electrical language, we can bridge the gap between genotype and phenotype, and ultimately bring more personalized, effective care to patients worldwide.' Greg Lipschitz, Chief Executive Officer of Firefly, said, 'As pharma and medtech organizations increasingly look to leverage the use of objective measures of brain activity such as EEG across various stages of new product development, from ideation up to and including commercialization, there is growing industry awareness and adoption of our highly differentiated, AI-powered technology. We are truly honored that a world-renowned physician scientist, like Prof. Schaaf, is the latest to see the value of his institution licensing our technology, and we look forward to updating our stakeholders as this important research is completed.'
Source
1 Stern T, Crutcher EH, McCarthy JM, Ali MA, Issachar G, Geva AB, Peremen Z, Schaaf CP. Brain Network Analysis of EEG Recordings Can Be Used to Assess Cognitive Function in Teenagers With 15q13.3 Microdeletion Syndrome. Front Neurosci. 2021 Jan 28;15:622329. doi: 10.3389/fnins.2021.622329. PMID: 33584189; PMCID: PMC7876406.
About Firefly
Firefly (NASDAQ: AIFF) is an Artificial Intelligence ('AI') company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly's FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.
Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly's extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG/ERP system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician's ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient's outcome.
Please visit https://fireflyneuro.com/ for more information.
About Prof. Christian Schaaf
Professor Schaaf is the Medical Director at Heidelberg University Hospital and Department Chair of the Institute of Human Genetics at the Heidelberg University in Germany. He studies the genetic causes of neurodevelopmental and neuropsychiatric disorders, including copy number variants of 15q13.3. His work led to the discovery of multiple new disease genes, and three disorders have been named after him: Schaaf-Yang syndrome, Bosch-Boonstra-Schaaf Optic Atrophy syndrome, and Marbach-Schaaf Neurodevelopmental syndrome.
Professor Schaaf's groundbreaking work has been recognized with many awards, including the William K. Bowes Award for Medical Genetics by Partners Healthcare and Harvard Medical School and the inaugural Seldin-Smith Award for Pioneering Research by the American Society for Clinical Investigation.
Forward-Looking Statements
Certain statements in this press release may constitute 'forward-looking statements' for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly's management teams' expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to those factors described under the heading 'Risk Factors' in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor & Media ContactStephen Kilmer(646) 274-3580stephen.kilmer@fireflyneuro.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Rivian vs. Lucid: Which EV Stock Is Winning in 2025?
Rivian vs. Lucid: Which EV Stock Is Winning in 2025?

Yahoo

time11 minutes ago

  • Yahoo

Rivian vs. Lucid: Which EV Stock Is Winning in 2025?

Key Points Rivian and Lucid both disappointed early investors. Both companies face supply chain issues and intense competition. But one of these EV companies has clearer near-term advantages. 10 stocks we like better than Rivian Automotive › Rivian (NASDAQ: RIVN) and Lucid (NASDAQ: LCID) were both hot electric vehicle (EV) stocks. Rivian went public with an IPO price of $78 on Nov. 10, 2021, and its shares more than doubled to a record closing price of $172.01 just a week later. Lucid went public by merging with a special purpose acquisition company (SPAC) on July 26, 2021. Its shares started trading at $25.24, and more than doubled to a record closing price of $55.52 four months later. Both companies initially attracted a stampede of bulls with their ambitious growth targets, and the buying frenzy in emotion-driven meme stocks amplified their gains. But today, Rivian and Lucid trade at about $13 and $3, respectively. Both stocks fizzled out as they missed their own goals and racked up steep losses. Rising rates also popped their bubbly valuations. But when interest rates declined in 2024, Rivian and Lucid didn't bounce back even as investors pivoted back toward more speculative stocks. That sentiment is still chilly: Rivian's stock has only risen 5% since the beginning of 2025, while Lucid's stock dipped 3%. Should contrarian investors consider buying either of these EV stocks right now? Why did Rivian and Lucid disappoint the market? Rivian sells three EVs: its R1T pickup, its R1S full-size SUV, and an electric delivery van (EDV) for its top investor, Amazon (NASDAQ: AMZN), and other companies. Before it went public, it claimed it could produce 50,000 vehicles in 2022. But in reality, it only produced 24,337 vehicles that year as it grappled with supply chain disruptions. Lucid sells two vehicles: its Air sedan and its new Gravity SUV. In its pre-merger presentation, it claimed it could deliver 20,000 vehicles in 2022. Unfortunately, it only delivered 4,369 vehicles in 2022 as it also struggled with supply chain constraints and production issues. At their record highs, Rivian's market cap hit $153.3 billion, or 92 times its 2022 revenue; while Lucid's market cap reached $91.4 billion, which was 150 times its 2022 revenue. Those sky-high valuations set both stocks up for steep declines when they missed their own rosy forecasts. What happened over the following years? In 2023, Rivian more than doubled its production to 57,232 vehicles as it overcame its supply chain issues. But in 2024, its production dipped to 49,476 vehicles as rising rates chilled the EV market, it faced tougher competition, and it temporarily shut down its main Illinois plant to upgrade its production capabilities. In 2025, it only expects to deliver 40,000 to 46,000 vehicles as it deals with higher tariffs on its raw materials and batteries, ongoing supply chain challenges, and another temporary shutdown to prepare for the launch of its smaller R2 SUV in 2026. Rivian is dealing with a lot of growing pains, but it's still supported by Amazon, Porsche (OTC: POAHY), Saudi Arabian conglomerate Abdul Latif Jameel, and other big investors. It ended its latest quarter with $8.5 billion in liquidity, and it expects the rollout of its smaller R2 SUV to significantly boost its sales and profits as it reaches a broader range of customers. Lucid's deliveries rose to 6,001 vehicles in 2023 and 10,241 vehicles in 2024, but those numbers were dismal compared to its original estimates. Lucid faced many of the same macro and competitive challenges as Rivian, and its CEO, Peter Rawlinson -- who attracted a lot of attention for his previous stint as Tesla's (NASDAQ: TSLA) chief vehicle engineer -- stepped down this February. Its board still hasn't appointed a permanent CEO yet. Rivian's founder and CEO, RJ Scaringe, remains in charge of his company. Lucid claims it can more than double its production to 20,000 vehicles this year as it ramps up its production of the Gravity SUV, but it doesn't have a great track record of meeting its own expectations. Yet Lucid is still firmly backed by Saudi Arabia's sovereign Public Investment Fund (PIF), which owns nearly two-thirds of its shares, and it ended its latest quarter with about $5.7 billion in liquidity, which it claims can carry it through its launch of the Gravity SUV. Which stock has more upside potential? From 2024 to 2027, analysts expect Rivian's revenue to grow at a compound annual growth rate (CAGR) of 32% as Lucid's revenue rises at a CAGR of 85%. Based on those estimates, which we should take with a grain of salt, Rivian and Lucid trade at 3.2 times and 6.9 times this year's sales, respectively. Neither company is expected to come close to breaking even, but Rivian's gross margins turned positive over the past two quarters as economies of scale kicked in. Lucid's gross margins are still negative. Rivian's higher production rates, healthier gross margins, and more stable leadership make it a stronger investment than Lucid right now -- even if its production wanes ahead of the R2's launch. As for Lucid, I'm not sure it can successfully ramp up its production of the Gravity and meet Wall Street's high expectations. If it falls short of that goal, its valuations will decline and its stock will drop even further. Should you buy stock in Rivian Automotive right now? Before you buy stock in Rivian Automotive, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Rivian Automotive wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Leo Sun has positions in Amazon. The Motley Fool has positions in and recommends Amazon and Tesla. The Motley Fool recommends Porsche Automobil Se. The Motley Fool has a disclosure policy. Rivian vs. Lucid: Which EV Stock Is Winning in 2025? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Breakthrough as two FDA-approved drugs are found to reverse Alzheimer's — including restoring memory
Breakthrough as two FDA-approved drugs are found to reverse Alzheimer's — including restoring memory

New York Post

time42 minutes ago

  • New York Post

Breakthrough as two FDA-approved drugs are found to reverse Alzheimer's — including restoring memory

In a stunning scientific discovery, researchers have found that a pair of drugs can not only slow down Alzheimer's disease but actually reverse it and restore memory in mice. And the best part of all? Both are already FDA-approved — albeit for cancer. Researchers first pinpointed how Alzheimer's disease scrambles gene activity in individual brain cells. 3 Researchers have found that a pair of drugs can not only slow down Alzheimer's disease but actually reverse it and restore memory in mice. Pixel-Shot – Using the Connectivity Map database of 1,300 FDA‑approved drugs, the researchers looked for medications that reverse Alzheimer's‑associated gene expression — landing on a shortlist of five, and zeroing in on two cancer drugs. In what one researcher called a 'mock clinical trial,' they then mined 1.4 million patients' medical records, finding that those who had taken letrozole or irinotecan for cancer were significantly less likely to develop Alzheimer's. When given together in an aggressive Alzheimer's mouse model, letrozole — used to treat certain types of breast cancer in postmenopausal women — and irinotecan — an anti-cancer medication used to treat colon cancer and small cell lung cancer — reversed disease‑related gene expression signatures, dissolved toxic tau protein clumps and prevented brain degeneration. Most importantly, they restored memory and learning in mice that had already developed severe symptoms. It's an exciting development for an illness that's notoriously tricky. 3 Letrozole — used to treat certain types of breast cancer in postmenopausal women — and irinotecan — an anti-cancer medication used to treat colon cancer and small cell lung cancer — reversed disease‑related gene expression signatures, dissolved toxic tau protein clumps and prevented brain degeneration. Eric Hood – 'Alzheimer's disease comes with complex changes to the brain, which has made it tough to study and treat, but our computational tools opened up the possibility of tackling the complexity directly,' Marina Sirota, the interim director of the UCSF Bakar Computational Health Sciences Institute, said in a statement. 'We're excited that our computational approach led us to a potential combination therapy for Alzheimer's based on existing FDA-approved medications.' 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health,' said Yadong Huang, a professor of neurology and pathology at UCSF. 'This makes it very challenging for drug development — which traditionally produces one drug for a single gene or protein that drives disease.' 3 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health,' said Yadong Huang, a professor of neurology and pathology at UCSF. yurakrasil – The findings were published in the journal Cell. Both drugs are already FDA‑approved for other uses, which could dramatically speed up the path to human trials. However, because they are cancer drugs, repurposing them may be complex and risky. This finding adds to a growing number of potential Alzheimer's treatments. A compound found in rosemary and sage — carnosic acid — has been shown to reverse memory loss and reduce brain inflammation in mice with Alzheimer's, bringing their cognitive function back to near-normal levels. A study from Stanford Medicine found that seniors who received the shingles vaccine were 20% less likely to develop dementia over seven years. And researchers at Penn State and Stanford University discovered that a certain cancer drug could restore memory and brain function in early stage Alzheimer's models.

‘It's an Easy Call,' Says Top Investor About Palantir Stock
‘It's an Easy Call,' Says Top Investor About Palantir Stock

Business Insider

timean hour ago

  • Business Insider

‘It's an Easy Call,' Says Top Investor About Palantir Stock

Palantir (NASDAQ:PLTR) stock, like any investment, requires weighing the potential rewards against the risks. While the company continues to perform exceptionally well, the primary – and arguably only – factor giving investors pause is its elevated share price. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. That concern hasn't slowed the stock's momentum. Palantir shares have surged by over 500% in the past 12 months, and late last week, the company reached yet another record high. Its valuation multiples now tower over sector medians by thousands of percentage points, raising questions about whether the fundamentals can keep pace with investor enthusiasm. Next week's Q2 earnings report, scheduled for August 4th, could provide a timely reality check. It offers a critical opportunity for the company to justify its lofty valuation – or fall short of the market's high expectations. Top investor Rick Orford, who's ranked among the top 1% of stock pickers on TipRanks, is leaning toward the former scenario. He anticipates another upswing in PLTR shares following the earnings release, making it an easy call given the current trajectory. 'Should Palantir hit its Q2'25 targets – and with how the wind is blowing, that could happen – I think Palantir shareholders will be pleased. His optimism is rooted in both historical performance and Palantir's current momentum. Historically, the stock has swung an average of 17.5% following earnings – a double-edged sword, but one that Orford believes will cut favorably this time. Central to that belief is the company's AI Platform (AIP), which helped drive a 39% year-over-year revenue increase last quarter. That growth has been especially notable in Palantir's U.S. commercial segment, where AIP adoption led to a 71% revenue spike in Q1. According to Orford, this surge reflects a broader trend: companies across the country are scrambling to implement AI but often lack the in-house expertise. Palantir's AIP provides them with a ready-made solution. 'American enterprises are most likely desperate to implement AI solutions, but not all of them have the technical expertise to do so. With AIP, these enterprises get what they need to implement custom AI into their operations,' the investor explains. Orford also sees Palantir's government work as a key stabilizing force. Its deep ties to the U.S. defense sector – with multi-year, high-margin contracts – offer a steady revenue stream that cushions any slowdown in the private market. 'Palantir checks all the boxes of an exciting, growing company that's at the intersection of two major trends: enterprise AI adoption and national defense modernization,' the investor sums up. 'Analysts say Hold, but history says otherwise.' Unsurprisingly, Orford gives PLTR shares a Strong Buy rating. (To watch Orford's track record, click here) The analyst consensus on PLTR is indeed a Hold, based on 10 Hold ratings, 4 Buys, and 3 Sells. The average 12-month price target stands at $109.50, implying a 31% downside from current levels. (See PLTR stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store